MedTrace Logo

The Glaucoma Nicotinamide Trial

NCT05275738 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2023-07-27

No results posted yet for this study

Summary

The Glaucoma Nicotinamide Trial (TGNT) is a prospective, randomized, placebo-controlled double-masked clinical trial composed of two cohorts; The Swedish Glaucoma Nicotinamide Trial (SGNT) and the Vitamin B3 In Glaucoma Study (VBIGS). Patients with open-angle glaucoma (OAG) will be randomized to receive either Nicotinamide or placebo through block randomization stratified by glaucoma subtype with a 1:1 allocation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide

Study tablets for nicotinamide are produced by Blackmores Ltd.

OTHER

Placebo

Study tablets for placebo are produced by Blackmores Ltd.

Sponsors & Collaborators

  • Center for Eye Research Australia

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Singapore National Eye Centre

    collaborator OTHER_GOV

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • University of Melbourne

    collaborator OTHER

  • University of Adelaide

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • Linkoeping University

    collaborator OTHER_GOV

  • Göteborg University

    collaborator OTHER

  • Umeå University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05275738 on ClinicalTrials.gov